| gap-pubmed-20260410- | What mechanisms cause Parkinson's disease in PARKIN mutation carriers if not mit | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is PARKIN's actual physiological function if not mitochondrial quality cont | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do PARKIN-deficient mouse models fail to recapitulate human Parkinson's dise | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do sphingolipid changes affect ALS disease progression rate and can this gui | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the causal relationship between ceramide metabolism disturbances and Lew | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do glucocerebrosidase mutations mechanistically drive α-synuclein transition | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the temporal relationship between escin's anti-inflammatory effects and | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does escin cross the blood-brain barrier to modulate central BDNF/TrkB and n | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do ASOs show efficacy in mouse models but face uncertain translation to huma | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines ASO target sequence specificity and off-target effects in neuron | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What drives the infarction-restricted proliferation of oligodendrocyte precursor | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What functional significance does the spatial proximity between osteopontin+ mye | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms drive the shared immuno-glial crosstalk between OPCs, | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What temporal dynamics and thresholds govern the transition from protective to p | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms determine whether ISR activation becomes neuroprotecti | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the mechanistic basis for p75NTR's dual pro-survival vs pro-apoptotic si | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does p75NTR modulation by LM11A-31 mechanistically link to cholesterol homeo | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What neuroplasticity mechanisms preserve hippocampal and prefrontal function und | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-plasticity |
| gap-pubmed-20260410- | How can animal models accurately capture human stress resilience mechanisms? | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | behavioral-neuroscience |
| gap-pubmed-20260410- | What are the causal mechanisms linking neural resilience systems to gut-brain ba | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-pubmed-20260410- | Which of the four reduced oligodendrocyte factors is most critical for neuronal | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does oligodendrocyte dysfunction cause selective loss of dopaminergic and mo | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link LXRβ to oligodendrocyte maturation and gene expre | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ligustilide specifically reverse ROS-induced BNIP3 downregulation? | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the temporal pattern of mitophagy inhibition during different SC | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does excessive ROS specifically block mitophagy flux at the molecular level? | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the functional significance of CC2D1A's postsynaptic localization for sy | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do CC2D1A's diverse cellular roles (nuclear, mitochondrial, vesicular) mecha | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | How do the newly identified gene targets MMP2 and NR3C1 mediate melatonin's ther | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which melatonin exerts neuroprotec | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the selectivity of late endosome-dependent versus canonical mito | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does SIRT1 specifically regulate Rab7-mediated late endosomal trafficking fo | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific FOXO4 target genes mediate the restoration of synaptic plasticity | open | 0.83 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | Why does FOXO activation through AKT inhibition promote neurogenesis when FOXO t | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurogenesis |
| gap-pubmed-20260410- | Why do different SGMS2 mutations cause opposite enzymatic effects but similar sk | open | 0.76 | 0.00 | 2026-04-10 | 0 | | metabolic-bone |
| gap-pubmed-20260410- | How does sphingomyelin synthase dysfunction cause peripheral facial nerve palsy | open | 0.79 | 0.00 | 2026-04-10 | 0 | | peripheral-neuropathy |
| gap-pubmed-20260410- | How do cytokines coordinate multiple cell death pathways simultaneously in strok | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines whether neuroinflammation after stroke is protective versus detr | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms mediate BIN1-Tau N368 obstruction of early-endosome re | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How does BIN1 overexpression rescue BDNF/TrkB endosome transport when BIN1-Tau N | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether gut microbiota-derived tryptophan metabolites are neurop | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do different tryptophan metabolites selectively activate AhR signaling in br | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which AhR activation disrupts bloo | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How should multi-targeted ASO approaches be designed to address AD's multifactor | open | 0.76 | 0.00 | 2026-04-10 | 0 | | gene-regulatory-networks |
| gap-pubmed-20260410- | Why do ASOs offer 'enhanced effects over alternative therapeutics' for AD treatm | open | 0.78 | 0.00 | 2026-04-10 | 0 | | molecular-targeted-therapy |
| gap-pubmed-20260410- | What determines optimal timing and disease stage for ASO delivery to maximize th | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does high-dose anti-IL-23 therapy compare to current approaches given neutro | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms explain secukinumab's failure in Behçet's uveitis despite IL-17 | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does anti-IL-17 therapy paradoxically induce Behçet's syndrome in some patie | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do dietary changes in uPDI show stronger ADRD associations than changes in o | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |